[Erythema multiforme following COVID-19 vaccination (BNT162b2)]

Hautarzt. 2022 Jan;73(1):68-70. doi: 10.1007/s00105-021-04911-4. Epub 2021 Oct 21.
[Article in German]

Abstract
in English, German

We report a case of a patient with erythema multiforme major following COVID-19 (coronavirus disease 2019) vaccination. Lesions on skin and mucous membranes developed 48 h after the second dose of the mRNA-vaccine BNT162b2 (Tozinameran, Comirnaty®). Under the application of external glucocorticoids complete resolution was achieved within 3 weeks.

Es wird über den Fall eines ausgeprägten Erythema exsudativum multiforme infolge einer COVID-19-Impfung berichtet. Die Effloreszenzen an Haut und Schleimhaut entwickelten sich 48 h nach der zweiten Dosis des mRNA-Impfstoffs BNT162b2 (Tozinameran, Comirnaty®). Unter der Anwendung glukokortikoidhaltiger Externa kam es innerhalb von 3 Wochen zu einer folgenlosen Abheilung.

Keywords: BNT162b2, tozinameran; Coronavirus disease 2019 vaccination; Erythema multiforme major; Hypersensitivity reaction; Interface dermatitis.

Publication types

  • Case Reports

MeSH terms

  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19*
  • Erythema Multiforme* / chemically induced
  • Erythema Multiforme* / diagnosis
  • Humans
  • SARS-CoV-2
  • Vaccination / adverse effects

Substances

  • COVID-19 Vaccines
  • BNT162 Vaccine